Document is current
Any future updates will be listed below
-
Authors
Scott, Susan C.
Farago, Anna
Lai, W. Victoria
Zahurak, Marianna
Rudek, Michelle A.
Murray, Judy
Carducci, Michael A.
Uziel, Tamar
Takebe, Naoko
Gore, Steven D.
Rudin, Charles M.
Hann, Christine L.
-
Funding
Funding for this research was provided by:
NCI (1UM1CA186709-01, 2UM1CA186691-06, 2UM1CA186691-06, 2UM1CA186691-06, 2UM1CA186691-06, 2UM1CA186691-06, 2UM1CA186691-06, 2UM1CA186691-06)
- License Information
-
More Information
Article History
Received: 3 November 2024
Accepted: 28 January 2025
First Online: 25 February 2025
Declarations
:
: SCS receives research funding direct to institution from Janssen, Mirati Therapeutics, and Black Diamond Therapeutics and has consulting relationships with AstraZeneca, Daiichi-Sankyo, Genentech, Janssen, Merus, and Regeneron. AFF is a current employee of Amgen and has stock ownership in Amgen and Novartis. WVL is a current employee of AstraZeneca and currently has stock ownership with AstraZeneca. TA is a current employee of AbbVie and may own stocks. CMR has consulted regarding oncology drug development with AbbVie, Amgen, AstraZeneca, Jazz, Mariana and Scorpion Therapeutics, and serves on the scientific advisory boards of Auron, DISCO, Earli, and Harpoon Therapeutics. CLH reports research funding direct to institution from AbbVIe, Amgen, AstraZeneca, Daiichi Sankyo and has a consulting relationship with AbbVie, Amgen, and AstraZeneca and serves on the scientific advisory boards of AstraZeneca and Daiichi Sankyo.
